drugset / Trial / NCT01935817

Silybin - Vitamin E- Phospholipids Complex Reduces Liver Fibrosis in Patients With Chronic Hepatitis C Treated With Peg-IFN-a and RBV

NCT01935817

Phase 3 Completed 64 enrolled University of Catania
RandomizedParallel-groupTriple-blindTreatment

Summary

Chronic hepatitis C is both a virologic and a fibrotic disease, with mortality resulting mainly from the complications of cirrhosis and HCC. The investigators' aim will be to evaluate the impact on of supplementation with a new pharmaceutical complex of silybin-vitamin E-phospholipids in patients with chronic hepatitis C treated with Pegylated-Interferon-α2b plus Ribavirin.

Timeline

Start
2010-06
Primary completion
2012-12
Completion
2012-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Silymarin Traditional medicine (herbal / TCM) 94 mg
Comparator Vitamin E Other / unclassified 90 mg